title: Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome.
abstract: Augmentation, defined as a loss of circadian recurrence with progressively earlier daily onset and increase in the duration, intensity, and anatomy of symptoms, not compatible with the half-life of the drug, is associated with dopaminergic treatment in restless legs syndrome (RLS) patients. The pathogenesis of augmentation is unclear. We describe a patient with idiopathic RLS who developed augmentation after 8 months of levodopa treatment. Videopolysomnographic and pharmacokinetic studies with monitoring of plasma levodopa levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with painful dysesthesia. Symptoms and signs of augmentation were related to low plasma levodopa levels, abating 75 minutes after oral levodopa administration and reappearing after 3 hours, closely mirroring the rapid rise and fall of plasma levodopa concentration. This case is the first report in which RLS augmentation is shown to be characterized by motor hyperkinesias paralleling levodopa plasma pharmacokinetic profile.
authors.affiliation: Department of Neurological Sciences, University of Bologna, Bologna, Italy. vetrugno@neuro.unibo.it
authors.forename: Roberto
authors.initials: R
authors.lastname: Vetrugno
authors.forename: Manuela
authors.initials: M
authors.lastname: Contin
authors.forename: Agostino
authors.initials: A
authors.lastname: Baruzzi
authors.forename: Federica
authors.initials: F
authors.lastname: Provini
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Plazzi
authors.forename: Pasquale
authors.initials: P
authors.lastname: Montagna
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D008657:Metabolic Clearance Rate / Q000502:physiology; D017286:Polysomnography; D012148:Restless Legs Syndrome / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D013035:Spasm / Q000097:blood / Q000139:chemically induced / Q000175:diagnosis
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa